AZD1656 is a potent, selective and orally active glucokinase activator with an EC50 of 60 nM. AZD1656 has the potential for type 2 diabetes research.
IC50&Target
EC50: 60 nM (Glucokinase)
体内研究
AZD1656 (0-9 mg/kg; oral gavage; daily; for 8 weeks; C57BL/6 mice) treatment shows lowered blood glucose and glucose excursion and raised insulin. Liver mRNA levels for various ChREBP target genes including carbohydrate response element binding protein beta isoform (ChREBP-β), G6pc, Pklr, Acly, Acac and Gpd2 are increased by AZD1656.
Animal Model:
C57BL/6 mice
Dosage:
0 mg/kg, 2 mg/kg, 4.5 mg/kg, 9 mg/kg
Administration:
Oral gavage; daily; for 8 weeks
Result:
Administered 2 hours before the oral glucose tolerance test, lowered blood glucose and glucose excursion and raised insulin.
分子式
C24H26N6O5
分子量
478.50
CAS号
919783-22-5
运输条件
Room temperature in continental US; may vary elsewhere.